Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Plastomics Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. Both matters are assigned to 1 examiner and 1 art unit, concentrating the prosecution activity in one examination setting.
SPEED, DEQUANTARIUS JAVON is the busiest examiner, with 2 pending matters. Consistent engagement with that examiner may support coordinated portfolio management.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPEED, DEQUANTARIUS JAVON | 2 | 70.0% | +69.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18180488 | PLASTID TRANSFORMATION BY COMPLEMENTATION OF NUCLEAR MUTATIONS | SPEED, DEQUANTARIUS JAVON | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18142777 | Plastid-transgene-encoded nuclear gene silencing | SPEED, DEQUANTARIUS JAVON | 12d |
| 18180488 | PLASTID TRANSFORMATION BY COMPLEMENTATION OF NUCLEAR MUTATIONS | SPEED, DEQUANTARIUS JAVON | — |
| Art Unit | Apps |
|---|---|
| 1663 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18142777 | Plastid-transgene-encoded nuclear gene silencing | SPEED, DEQUANTARIUS JAVON | 1663 | §112 | Non-Final OA | 12d | Pending | May 03, 2023 |
| 18180488 | PLASTID TRANSFORMATION BY COMPLEMENTATION OF NUCLEAR MUTATIONS | SPEED, DEQUANTARIUS JAVON | 1663 | §103§112 | Final Rejection | — | Pending | Mar 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPlastomics Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dequantarius Javon Speed has the most, with 2 of Plastomics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
